The
latest market report published by Credence Research, Inc. “Global Genital
Herpes Treatment Drugs Market By Drug Class (Acyclovir,
Famciclovir and Valacyclovir) - Growth, Future Prospects & Competitive
Analysis, 2018 - 2026,” the global genital herpes treatment drugs
market is expected to expand at a CAGR of 4.9% from 2018 to 2026.
Market
Insights
Genital
herpes is the most common form of sexually transmitted disease in sexually
active person. In the earlier stage of infection there are no visible symptoms
reported but as the disease progresses genital lesions, cold sores, abnormal
discharge and excruciating pain during micturition are clinically manifested.
It is spread through oral, vaginal and anal contact. It is important to note
that herpes infection is not cured only the symptoms are suppressed to promote
relief in the ailing patients. Safe sex practice, early diagnosis and genital
hygiene are the best preventive care to curb the spread of genital herpes
infection. There is a changing trend in the treatment of genital herpes
infection, wherein biologist are primarily focusing on developing vaccines to
bolster immunity in ailing patients and address the problem of lesion
recurrence.
Browse
the full report Genital Herpes
Treatment Drugs Market - Growth, Future Prospects, Competitive Analysis,
2018 – 2026 report at https://www.credenceresearch.com/report/genital-herpes-treatment-drugs-market
Acyclovir
is presently dominating the drug class for the genital herpes treatment drugs
market. The primary features responsible for the dominance of acyclovir are its
excellent therapeutic efficacy, dose tolerance with negligible toxicity. It is
currently the drug of first choice for the treatment of genital herpes with a
prescribed dose of 200 mg five times daily for 10 days. Famciclovir has gained
prominence on account of its higher oral bioavailability which is employed for
the treatment of genital herpes patients suffering with lesion recurrence.
North
America is currently reigning the geographical segment for genital herpes
treatment drugs market. According to Center for Disease Control and Prevention
(CDC), genital herpes is occurring 1in every 6 citizens in the United States.
Rising prevalence of sexually transmitted disease and effective treatment
guidelines drive the genital herpes treatment drugs market growth in North
America. Affordable reimbursement scenario and domicile of major players such
as AstraZeneca, Plc., GlaxoSmithkline, Plc. & Novartis AG. Propel the
genital herpes treatment drugs market growth in the European region. Asia
Pacific will register rapid growth during the forecast period from 2018 to 2026
owing to the rising prevalence of HSV-1 infected patients, increasing public
health awareness and presence of huge generic drugs for the treatment of
genital herpes infection.
Pharmaceutical
companies providing medication for the treatment of genital herpes infection
are AstraZeneca, Plc., Apotheca, Inc., Asahi Kasei Pharma Corporation, Carlsbad
Technology, Inc., GlaxoSmithkline, Plc., Mylan N.V., Novartis AG., Merck &
Co., Inc., Teva Pharmaceutical Industries Ltd. and Zydus Pharmaceuticals, Inc.
Key
Market Movements:
- Rising
prevalence of sexually transmitted disease worldwide
- Increasing
public health awareness and affordable reimbursement scenario drive the
genital herpes treatment drugs market
- Excellent
product pipeline catering therapeutics vaccines to bolster patient
immunity such as GEN-003 and VCL-HB01
Download Free PDF
Sample Request: https://www.credenceresearch.com/sample-request/59515
Table of Content
Chapter 1.
Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation
Chapter 2.
Executive Summary
2.1. Global Genital Herpes Treatment Drugs Market Portraiture
2.2. Global Genital Herpes Treatment Drugs Market, by Drug Class, 2017 (US$ Mn)
2.3. Global Genital Herpes Treatment Drugs Market, by Geography, 2017 (US$ Mn)
2.1. Global Genital Herpes Treatment Drugs Market Portraiture
2.2. Global Genital Herpes Treatment Drugs Market, by Drug Class, 2017 (US$ Mn)
2.3. Global Genital Herpes Treatment Drugs Market, by Geography, 2017 (US$ Mn)
Chapter 3.
Genital Herpes Treatment Drugs Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Genital Herpes Treatment Drugs Market, by Key Players, 2017
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Genital Herpes Treatment Drugs Market, by Key Players, 2017
Chapter 4. Global
Genital Herpes Treatment Drugs Market, by Drug Class
4.1. Overview
4.2. Acyclovir
4.3. Famciclovir
4.4. Valacyclovir
4.5. Pipeline Analysis
4.5.1. Phase III Drugs
4.5.1.1. GEN-003
4.5.1.2. VCL-HB01
4.5.2. Tabular Representation of Drug Pipeline in Phase II and I
4.1. Overview
4.2. Acyclovir
4.3. Famciclovir
4.4. Valacyclovir
4.5. Pipeline Analysis
4.5.1. Phase III Drugs
4.5.1.1. GEN-003
4.5.1.2. VCL-HB01
4.5.2. Tabular Representation of Drug Pipeline in Phase II and I
Chapter 5. Global
Genital Herpes Treatment Drugs Market, by Geography
5.1. Overview
5.2. North America Genital Herpes Treatment Drugs Market Analysis, 2016 – 2026
5.2.1. North America Genital Herpes Treatment Drugs Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.2.2. North America Genital Herpes Treatment Drugs Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Genital Herpes Treatment Drugs Market Analysis, 2016 – 2026
5.3.1. Europe Genital Herpes Treatment Drugs Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.3.2. Europe Genital Herpes Treatment Drugs Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Genital Herpes Treatment Drugs Market Analysis, 2016 – 2026
5.4.1. Asia Pacific Genital Herpes Treatment Drugs Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific Genital Herpes Treatment Drugs Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America Genital Herpes Treatment Drugs Market Analysis, 2016 – 2026
5.5.1. Latin America Genital Herpes Treatment Drugs Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.5.2. Latin America Genital Herpes Treatment Drugs Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East and Africa Genital Herpes Treatment Drugs Market Analysis, 2016 – 2026
5.6.1. MEA Genital Herpes Treatment Drugs Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.6.2. MEA Genital Herpes Treatment Drugs Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA
5.1. Overview
5.2. North America Genital Herpes Treatment Drugs Market Analysis, 2016 – 2026
5.2.1. North America Genital Herpes Treatment Drugs Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.2.2. North America Genital Herpes Treatment Drugs Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Genital Herpes Treatment Drugs Market Analysis, 2016 – 2026
5.3.1. Europe Genital Herpes Treatment Drugs Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.3.2. Europe Genital Herpes Treatment Drugs Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Genital Herpes Treatment Drugs Market Analysis, 2016 – 2026
5.4.1. Asia Pacific Genital Herpes Treatment Drugs Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific Genital Herpes Treatment Drugs Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America Genital Herpes Treatment Drugs Market Analysis, 2016 – 2026
5.5.1. Latin America Genital Herpes Treatment Drugs Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.5.2. Latin America Genital Herpes Treatment Drugs Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East and Africa Genital Herpes Treatment Drugs Market Analysis, 2016 – 2026
5.6.1. MEA Genital Herpes Treatment Drugs Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.6.2. MEA Genital Herpes Treatment Drugs Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA
Chapter 6.
Company Profiles
6.1. AstraZeneca, Plc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Apotheca, Inc.
6.3. Asahi Kasei Pharma Corporation
6.4. Carlsbad Technology, Inc.
6.5. GlaxoSmithKline plc.
6.6. Mylan N.V.
6.7. Novartis AG
6.8. Merck & Co., Inc.
6.9. Teva Pharmaceutical Industries Ltd.
6.10. Zydus Pharmaceuticals, Inc.
6.1. AstraZeneca, Plc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Apotheca, Inc.
6.3. Asahi Kasei Pharma Corporation
6.4. Carlsbad Technology, Inc.
6.5. GlaxoSmithKline plc.
6.6. Mylan N.V.
6.7. Novartis AG
6.8. Merck & Co., Inc.
6.9. Teva Pharmaceutical Industries Ltd.
6.10. Zydus Pharmaceuticals, Inc.
By Geography
Segment (2016–2026; US$ Mn)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Do Enquiry before
Buying for research report: https://www.credenceresearch.com/inquiry-before-buying/59515
About Us
Credence Research is a worldwide market research and
counseling firm that serves driving organizations, governments, non legislative
associations, and not-for-benefits. We offer our customers some assistance with
making enduring enhancements to their execution and understand their most
imperative objectives. Over almost a century, we've manufactured a firm
extraordinarily prepared to this task.
Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
Toll-Free (US/CANADA) Ph.: +1-800-361-8290
No comments:
Post a Comment